Entera Bio (ENTX) revenue and earnings history
Entera Bio reported revenue of $42K for fiscal 2025 (year ended Dec 31, 2025), −76.8% on the year before, and net income of −$11.4M.
Over 5 years, from fiscal 2020 to fiscal 2025, revenue grew at a compound rate of −35.1% a year.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $42K−76.8% | −$11.5M | −$11.4M | −$7.37M | $107K | −$7.48M | $2.75M | — | — | $7.11M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Entera Bio (ENTX) on OQRO.
Common questions
What was Entera Bio's revenue in fiscal 2025?
$42K for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 27, 2026. That is −76.8% on fiscal 2024 ($181K).
How fast has Entera Bio's revenue grown?
From $365K in fiscal 2020 to $42K in fiscal 2025: a compound annual growth rate of −35.1% over 5 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Entera Bio been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Entera Bio tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
